RxDoctor Payments DataLook up a doctor →

Rachel Wint, PA

Surgical · Mount Laurel, NJNPI 1649751843

Payments from drug & device makers

$10,385in general payments, 2019–2025

Across 417 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myovant Sciences Inc.$1K
  • Johnson & Johnson$873
  • Bayer$864
  • Astellas Pharma US Inc$692
  • Sumitomo Pharma America, Inc.$553
  • Novartis$546
  • plus $6K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Myovant Sciences Inc.41$1,141
Johnson & Johnson38$873
Bayer31$864
Astellas Pharma US Inc40$692
Sumitomo Pharma America, Inc.24$553
Novartis24$546
Janssen Scientific Affairs, LLC5$541
Medtronic8$455
Teleflex LLC8$303
Sanofi11$278
Dendreon Pharmaceuticals LLC10$243
Incyte Corporation9$221
Eisai Inc.10$210
AstraZeneca(2 entities)12$203
AbbVie7$200
Tolmar Pharmaceuticals, Inc.4$190
Tolmar, Inc.10$187
Merck9$157
Pfizer10$147
Blue Earth Diagnostics6$135
Urovant Sciences Inc8$126
Pharmacyclics LLC, An Abbvie Company5$113
Gilead2$110
Urogen Pharma, Inc.6$109
Sun Pharmaceutical Industries Inc.5$102
Axonics, Inc.1$102
Pharmacosmos Therapeutics Inc.4$93
Foundation Medicine, Inc.5$93
Agiliti Surgical, Inc.1$92
AVEO Pharmaceuticals, Inc.4$86
Accord Healthcare, Inc.4$72
Emmaus Medical, Inc.3$71
Acceleron Pharma, Inc.3$65
Clarus Therapeutics Inc.3$65
Progenics Pharmaceuticals, Inc.3$64
Telix Pharmaceuticals3$57
Amgen2$54
Kyowa Kirin, Inc.3$52
C. R. Bard, Inc. & Subsidiaries2$49
Adaptive Biotechnologies Corporation2$44
Coloplast2$38
Jazz Pharmaceuticals Inc.2$36
Endo Pharmaceuticals Inc.2$34
Novocure Inc.1$31
Palette Life Sciences, Inc.1$30
Boston Scientific2$28
Beigene USA, Inc.1$28
Regeneron Healthcare Solutions, Inc.1$26
Apellis Pharmaceuticals, Inc.1$26
Amneal Pharmaceuticals LLC1$25
Takeda Pharmaceuticals U.S.A., Inc.1$25
Global Blood Therapeutics, Inc.1$24
Genmab U.S., Inc.1$24
Puma Biotechnology, Inc.1$23
Daiichi Sankyo Inc.1$23
Clovis Oncology, Inc.1$21
Ipsen Biopharmaceuticals, Inc1$20
Coherus Oncology, Inc.1$19
Sobi, Inc1$18
Taiho Oncology, Inc.1$18

How this compares

$10,385 in reported general payments places this provider in the 95th percentile of 462 surgical providers in New Jersey.

See all surgical providers in New Jersey

Medicare billing

Part B allowed, 2024
$62,979
Medicare patients
80
Services billed
1,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical in Mount Laurel

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →